Company intelligence / Profile preview
StarkAge Therapeutics
Lille, Hauts-de-France, Francestarkagetx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
StarkAge Therapeutics has demonstrated promising in vitro and in vivo results for its lead ADC candidate STX‑1, which targets DPP4-expressing senescent cells. The company aims to finalize preclinical studies for STX‑1 in various cancer models and initiate further programs such as STX‑2. Early data suggest broad applicability across multiple age-related pathologies where cellular senescence plays a role.[3]
- Therapeutic areas
- PulmonologyOncologyMetabolic DisordersOtherGastroenterologyNeurology
- Modalities
- Antibody-drug conjugates (ADC)ImmunotherapyExosomal and extracellular vesicle technology
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
National Institute of Health/Professor Myriam Gorospe collaboration on cellular senescence research[3]
Beyond the preview
Go deeper on StarkAge Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on StarkAge Therapeutics.